Standard lymphodepletion regimen
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stiff-Person Syndrome
Conditions
Stiff-Person Syndrome, SPS
Trial Timeline
Sep 25, 2024 → Dec 1, 2026
NCT ID
NCT06588491About Standard lymphodepletion regimen
Standard lymphodepletion regimen is a phase 2 stage product being developed by Kyverna Therapeutics for Stiff-Person Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT06588491. Target conditions include Stiff-Person Syndrome, SPS.
What happened to similar drugs?
0 of 1 similar drugs in Stiff-Person Syndrome were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06588491 | Phase 2 | Active |
Competing Products
1 competing product in Stiff-Person Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intravenous Immunoglobulins, Human + Placebos | Grifols | Phase 3 | 29 |